Literature DB >> 10934606

[Clinical features of multiple primary cancers including prostate cancer].

S Nakata1, H Takahashi, Y Takezawa, M Kobayashi, T Suzuki, K Kawashima.   

Abstract

We analyzed the clinical features of multiple primary cancers (MPCs) that included prostate cancer. MPCs were observed in 93 (15.2%) of the patients suffering from prostate cancer. In the MPC group, the organ most commonly involved was the stomach, followed by bladder, colon and lungs. The median age at diagnosis of the first, second and third cancers was 72, 74, and 75 years old, respectively, and the duration between the first and second cancers (median: 20 months) was longer than that between the second and third cancers (median: 8 months). In the 37 MPC patients whose cause of death was obvious, 29 (78.4%) died of a cancer; prostate cancer was not so common (6 patients) as the cause of death. Age at diagnosis and grade distribution of prostate cancer were not significantly different between the MPC and single primary cancer (SPC) groups. However, the proportion of earlier stage was significantly (p < 0.01) higher in the MPC group than in the SPC group, and this trend was more obvious in patients whose prostate cancer was diagnosed as the second cancer. The prostate cancer-specific survival rates were significantly higher in the patients with MPC, and this trend was more obvious in the patients with stage D or moderately differentiated cancer. It is important in the follow up of prostate cancer patients to be aware of the possibility of the occurrence of a second cancer.

Entities:  

Mesh:

Year:  2000        PMID: 10934606

Source DB:  PubMed          Journal:  Hinyokika Kiyo        ISSN: 0018-1994


  2 in total

1.  Multiple primary neoplasms developing in a case of prostate cancer.

Authors:  D Kulkarni; G A B Miller
Journal:  Ulster Med J       Date:  2003-05

2.  Multidisciplinary treatment based on surgery leading to long-term survival of a patient with multiple asynchronous rare primary malignant neoplasms: A case report and literature review.

Authors:  Hong-Lin Gu; Shi-Xing Zeng; Yun-Bing Chang; Zhen Lin; Qiu-Jian Zheng; Xiao-Qing Zheng; Zhen-Wei Peng; Shi-Qiang Zhan
Journal:  Oncol Lett       Date:  2014-12-29       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.